14
Participants
Start Date
March 31, 2008
Primary Completion Date
May 31, 2009
Study Completion Date
May 31, 2009
Carbidopa/levodopa/entacapone
Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
Immediate release carbidopa/levodopa
Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
Parkinson's Disease & Movement Disorders, Commack
Central New York Research Corporation, Syracuse
Neurological Care of Central NY, Syracuse
Neurology Associates, Monroeville
University of Pittsburg, Pittsburgh
Georgetown University Hospital, Washington D.C.
University of Maryland School of Medicine, Baltimore
Duke University, Durham
Sunrise Clinical Research, Inc, Hollywood
Charlotte Neurological Services, Port Charlotte
Dr. John's Mercy Medical Center, St Louis
Neurology, Inc, Columbia
Cotton O'Neil Clinic, Topeka
Creighton U Medical Center, Dept of Neurology, Omaha
University of Texas Southwestern, Dallas
Scott & White Hospital, Temple
University of Texas Medical School, Houston
Xenoscience, Inc, Phoenix
Coastal Neurological Medical Group, Inc, La Jolla
South Coast Health Center, Aliso Viejo
University of California, Irvine
Lead Sponsor
Novartis
INDUSTRY